Last reviewed 2026-05-29 · How we verify

Parimparib

Affiliated Hospital of Jiangnan University · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Parimparib is a Small molecule drug developed by Affiliated Hospital of Jiangnan University. It is currently in Phase 1 development. Also known as: BGB-290, Poly (ADP-ribose) polymerase (PARP) inhibitor.

Pamiparib (BGB-290) is a targeted therapy agent used to treat EGF-R positive non-small cell lung cancer that is resistant to EGFR tyrosine kinase inhibitors. It is also being studied in combination with chemotherapy for non-small cell lung cancer.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Parimparib
Also known as	BGB-290, Poly (ADP-ribose) polymerase (PARP) inhibitor
Sponsor	Affiliated Hospital of Jiangnan University
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Parimparib CI brief — competitive landscape report
Parimparib updates RSS · CI watch RSS
Affiliated Hospital of Jiangnan University portfolio CI

Frequently asked questions about Parimparib

What is Parimparib?

Parimparib is a Small molecule drug developed by Affiliated Hospital of Jiangnan University.

Who makes Parimparib?

Parimparib is developed by Affiliated Hospital of Jiangnan University (see full Affiliated Hospital of Jiangnan University pipeline at /company/affiliated-hospital-of-jiangnan-university).

Is Parimparib also known as anything else?

Parimparib is also known as BGB-290, Poly (ADP-ribose) polymerase (PARP) inhibitor.

What development phase is Parimparib in?

Parimparib is in Phase 1.

Manufacturer: Affiliated Hospital of Jiangnan University — full pipeline
Therapeutic area: All drugs in Other
Also known as: BGB-290, Poly (ADP-ribose) polymerase (PARP) inhibitor

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing